A carregar...
Chronic myelogenous leukemia on target
Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro‐leukemic activity of the BCR‐ABL1 oncoprotein. Despite the therapeutic progress mediated by TKI use, off‐target effects, treatment‐induced drug resistance, and the limited effect of the...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6051163/ https://ncbi.nlm.nih.gov/pubmed/29905026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1604 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|